Stanley Bruce Malkowicz, MD
Incidence and Etiology
Retroperitoneal sarcomas are relatively rare lesions that comprise nearly 15% of the soft tissue sarcomas that occur annually and thus account for approximately 2000 cases per year (Jemal, 2009). Surveillance, Epidemiology, and End Results (SEER) data from the U.S. National Cancer Institute have identified 2.7 cases per 100,000 individuals at a steady rate over the past 30 years (Porter, 2006). Actually, fewer than half of all retroperitoneal tumors are sarcomas. Fifteen to 20 percent are benign lesions such as lipomas, and the remainder consist of primary lymphoma or primary urologic tumors such as germ cell lesions (Jemal et al, 2002). Presentation is usually in the sixth decade of life, but the age range is broad (Gronchi et al, 2009). There is a slight male predominance, and two thirds of patients have high-grade malignancy. Approximately 10% will present with metastatic disease, with lung and liver the most common sites of spread (Lewis, 1998).
The etiology of retroperitoneal sarcoma is poorly understood. The etiology of sarcoma has been attributed to prior radiation exposure and toxins, yet it is difficult to account for this in the majority of cases. Approximately 0.1% of patients who receive radiation therapy may develop a sarcoma at the treatment site. The most common lesion associated with radiation is malignant fibrous histiocytoma. Some association exists between dioxin exposure and the development of sarcoma, but prolonged periods of exposure and significant latency were also noted (Hardell and Sandstom, 1979).
Pathology
Retroperitoneal sarcomas arise primarily from soft tissues of fibrous and adipose origin as well as muscle, nerve, and lymphatic tissue. These tissues are derived from primitive mesenchyme from the mesoderm with some contribution from neuroectoderm (Economou, 1987). Their location allows for a rather long indolent preclinical course during which time the tumor can grow to significant proportions. This growth may result in local areas of necrosis or liquefaction as the tumor outstrips its vascular supply.
In classic reviews of these lesions the common tissue distribution in descending order is liposarcoma, leiomyosarcoma, and fibrosarcoma, followed by other histologies (McGrath et al, 1984; Karakousis et al, 1985, Jacques et al, 1990; Storm and Mahvi, 1991; Rossi et al, 1993). Malignant fibrous histiocytoma is expressed more prominently in contemporary series; however, owing to intensive pathologic interest in defining this disorder, many tumors previously described as variants of fibrosarcoma or liposarcoma have been reclassified as malignant fibrous histiocytoma (Rööser et al, 1991; Pezzi et al, 1992). Therefore fibrosarcoma has been replaced in frequency order by this condition.
Additionally, several previously characterized leiomyosarcomas are now correctly identified as gastrointestinal stromal tumors. By various histologic and immunohistochemical stratification it became apparent that these tumors were less like smooth muscle and more similar to cells of the myenteric nervous system. It is now believed that these tumors probably originate from stem cells that differentiate toward an interstitial cell of Cajal phenotype (Table 52–1) (Quek and George, 2009).
Benign |
Malignant |
The molecular pathology of sarcomas is complex, and many lesions demonstrate the theme of specific chromosomal translocations creating a fusion chimeric transcription factor. A sophisticated understanding of these changes has been further developed in lesions less commonly seen in the adult retroperitoneum. A partial list of these alterations is presented in Table 52–2. These factors interact with the upstream regulatory component of a gene and can significantly affect the expression of that gene at the messenger RNA level. The nucleic acid binding domain of the chimeric transcription factor confers target specificity within the tissue genome while the transcription factor portion of this novel protein determines the transactivation potential and expression level of the target gene (Crozat et al, 1993; Ladanyi, 1995; Panagopoulos et al, 1996; Tschoep et al, 2007; Torsten and West, 2010). The description of this pathologic mechanism predated a similar finding recently described in prostate cancer.
TUMOR | ABERRATION | GENE(S) INVOLVED |
---|---|---|
Alveolar rhabdomyosarcoma | t(2;13) (q35;q14) | PAX3-FKHR |
t(1;13) (p36;q14) | PAX7-FKHR | |
Myxoid/round cell liposarcoma | t(12;16) (q13;p11) | TLS-CHOP |
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS) | Supernumerary ring chromosomes; giant marker chromosomes | Amplification of region 12q14-15, Including MDM2, CDK4, HMGA2, SAS, GL1 |
Dedifferentiated liposarcoma | Same as for ALT/WDLPS | Same as for ALT/WDLPS |
Sporadic gastrointestinal stromal tumor | Activating kinase mutations | KIT or PDGFRA |
Additionally, the development of extra abnormal chromosomes (ring chromosomes and giant rods) involving chromosome 12 can result in the amplification of certain gene products such as MDM2 and SAS. MDM2 can be involved in TP53 inactivation, which can contribute to carcinogenesis (Berner et al, 1996; Elkahloun et al, 1996). Series of investigations regarding soft tissue leiomyosarcoma have revealed exceptionally complex, multiple gene alterations that are not easily categorized. These molecular insights into the pathology of sarcoma have not translated into therapeutic targets as readily as the gastrointestinal stromal tumors histology but may provide approaches for future therapeutic strategies directed at these lesions (Van Roggen and Hogendoorn, 2000; Nielson and West, 2010).
Gastrointestinal stromal tumors demonstrate activated c-KIT mutations in 8% to 88% of lesions. Additionally, analogous gain of function mutations were demonstrated in platelet-derived growth factor receptor-α (PDGFR-α). These mutations suggested a role for targeted therapy in these lesions (Heinrich et al, 2003; Corless et al, 2004).
Benign Lesions
Lipomas
Lipomas consist almost entirely of mature fat and are uncommonly found in the retroperitoneum. They are probably the most common soft tissue tumor in humans. Most of these lesions occur superficially, but they may occur in other areas, such as the retroperitoneum. Deep lipomas within the retroperitoneum are usually not as well circumscribed as their superficial counterparts and can conform to irregular spaces in this body space (DeWeerd and Dockerty, 1952; Mowat and Clark, 1961). The adipocytes are normal or slightly larger in appearance and have a well-developed vascular network. There is very little in the way of nuclear irregularity. Differing levels of fibrous connective tissue can be found in these lesions. The rim of the lipocyte is reactive for S-100 protein. Although the majority of these masses are idiopathic, they can occasionally be a manifestation of steroid lipomatosis.
Pelvic lipomatosis, although not a distinct tumor per se, was first described in 1959 as an overgrowth of fat in the perivesical and perirectal area. It is a hyperplastic rather a neoplastic entity that can create a space-occupying lesion. Approximately two thirds of patients are African-American, and women are rarely affected (Heyns, 1991). The growth is diffuse rather than nodular, and often it is difficult to distinguish it from normal adipose tissue. The condition may be associated with cystitis glandularis (Yalla et al, 1975). The general clinical course is slowly progressive and may result in the need for urinary diversion (Klein et al, 1988). Occasionally, fat necrosis in these lesions can be mistaken for sarcomatous degeneration (Andac et al, 2003).
Myelolipoma
Myelolipoma is a tumor-like growth of mature fat and bone marrow elements. Although it usually occurs in the adrenal gland it can be seen as an isolated pelvic lesion (Chen et al, 1982; Sanders et al, 1995). It is distinct from extramedullary hematopoietic tumors, which are usually multiple and generally associated with mild proliferative diseases and skeletal disorders. These generally occur in patients older than age 40 years and are rarely greater than 5 cm (Fowler et al, 1992; Mukherjee et al, 2010). They are usually noted as incidental findings on imaging. The adrenal gland can create inferior renal displacement due to a radiolucent mass. Pathologically it may display the features of a lipoma or have a darker appearance if myeloid elements predominate. Adrenal myolipoma development may be secondary to prolonged stress and excessive stimulation with adrenocorticotropic hormone.
Leiomyoma
These generally rare lesions are seen in a distribution that represents smooth muscle tissue in the body. They are overwhelmingly found in the female genital tract but have also been reported in the urinary bladder. There are occasional reports of these tumors in the retroperitoneum, where they can grow asymptomatically to a considerable size. Leiomyomas stain positive for desmin, which separates them from their malignant counterpart. Extension of these lesions from the uterus into the vascular system can create tumor thrombi not unlike those seen with renal lesions (Clement, 1988).
Malignant Lesions
Liposarcoma
Liposarcomas are among the most common of primary retroperitoneal tumors and are distinguished by their often large dimensions and range of subtypes. These lesions have their peak incidence between ages 40 and 60 (Kindblom et al, 1975). They account for 10% to 15% of sarcomas, and approximately 20% of these lesions arise in the retroperitoneum. One unfortunate clinical feature of these lesions is their usual tendency to recur, often within the first 6 months after surgery. The principal tissue type is usually recapitulated at the time of recurrence. The rate of metastasis depends on the degree of tumor differentiation, with nearly 90% of poorly differentiated tumors metastasizing (Enterline et al, 1960; Spittle et al, 1971; Weiss and Rao, 1992).
Significant advances in cytogenetics have allowed the reclassification of these lesions on a molecular basis. Well-differentiated and dedifferentiated lesions are a continuum of lesions based on the genetic abnormality of giant and ring chromosomes usually involving chromosome 12. Gene amplification, particularly of MDM2, drives their pathology (Pilotti et al, 1998; Forus et al, 2001). Myxoid and round cell lesions (poorly differentiated myxoid) are another continuum that have fusion transcripts caused by translocations in chromosomes 16 and 12 as their principal pathologic feature. Pleomorphic liposarcomas are rare and poorly understood (Dal Cin et al, 1997).
Myxoid liposarcomas are the most common type and usually occur in the lower extremity. They account for 50% of sarcomas and represent a large proportion of retroperitoneal lesions. The peak presentation is in the fifth decade. These tumors display a background of stellate mesenchymal cells and a prominent capillary pattern often described as a “chicken wire” appearance. The distinct cell is the lipoblast, which is similar to the fetal adipocyte. These cells are noted by a lipid vacuole that scallops the nucleus. This creates the lipoma-like appearance of these lesions, which can demonstrate fusion proteins (TLS-CHOP) on molecular analysis. Higher-grade lesions tend to demonstrate a higher number of TP53 mutations (Deitos et al, 1997). The round cell subtype is also referred to as a lipoblastic variant and is distinguished by sheets of round cells with lipoblastic differentiation. These lesions are considered the most aggressive part of the spectrum of myxoid lesions.
Leiomyosarcoma
Grossly, low-grade leiomyosarcomas can be difficult to distinguish from leiomyomas but higher-grade lesions display a more infiltrative fleshlike appearance (Shmookler and Lauer, 1983). Low-grade lesions are often distinguished from leiomyomas by their chromatin pattern and the number of mitoses (more than five mitoses per high-power field) present in the specimen.
A rare retroperitoneal variant of these tumors are leiomyosarcomas that originate from the great vessels (Demers et al, 1992). These occur predominantly in women. Tumors of the iliac vessels usually present as lower extremity edema, whereas those of the inferior vena cava can display findings consistent with Budd-Chiari syndrome (Cardell et al, 1971). Resection of these lesions is recommended when anatomically feasible. Survival, however, is usually less than 2 years, and many inferior vena caval tumors are unresectable because of the intrahepatic location of many of these lesions.
Malignant Fibrous Histiocytoma
Malignant fibrous histiocytoma was originally described in 1963 and has come to be the predominant histologic diagnosis for currently reported soft tissue sarcomas (Ozello et al, 1963). It was first defined as a sarcoma of primary histiocytic origin, but it is now believed that it is a lesion derived from fibroblast differentiation. Many pleomorphic variants of fibrosarcoma, liposarcoma, and rhabdomyosarcoma have been reclassified into this category. With the thorough evaluation of a tumor specimen, distinct regions of leiomyosarcoma, liposarcoma, and other soft tissue sarcomas may be identified. In such cases the tumor may be defined by those findings and the mention of an associated malignant fibrous histiocytoma pattern (Weiss, 1982). These lesions are most often seen on the extremities and are less common in the retroperitoneum. Their molecular pathology is unclear. An analysis of these lesions in the retroperitoneum suggests that many of these could be reclassified as a dedifferentiated liposarcoma and that they may represent a common end point for several tissue types (Coindre et al, 2003; Tschoep et al, 2007). Storiform-pleomorphic, myxoid, giant cell, and inflammatory subtypes of malignant fibrous histiocytoma may coexist in a particular lesion.
Fibrosarcoma
Fibrosarcomas are malignant tumors of fibroblast origin. They have a range of gradation and grossly display a classic “fish flesh” pattern with hemorrhage and necrosis. Low-grade lesions can display a herringbone/spindle-shaped histologic pattern. On retrospective review these lesions are often reclassified as malignant fibrous histiocytoma or as a desmoid lesion (aggressive fibromatosis). Therefore these lesions represent a smaller proportion of primary retroperitoneal tumors than previously reported. There is a greater incidence of blood-borne metastases from this tumor to the lung and bones (Bizer, 1971).
Rhabdomyosarcoma
Rhabdomyosarcoma comprises a minor percentage of reported retroperitoneal sarcomas yet is a significant lesion in pediatric oncology as well as pediatric tumors associated with the genitourinary system. These lesions are generally classified as embryonal, botryoid, alveolar, or pleomorphic, with a spindle cell subtype more recently described within the embryonal type (Horn and Enterline, 1958; Cavazzana et al, 1992). The pathology of these lesions is associated with chromosomal abnormalities and the fusion transcripts associated with these translocations.
Malignant Hemangiopericytoma
These rare lesions originate from pericytes, which are unique cells that arborize about small vessels and capillaries. Their contractile properties allow them to control microvascular flow and permeability. Fewer than 200 of these lesions have been described, yet 25% of them have occurred in the retroperitoneum or pelvis. They are usually well circumscribed and, if possible, complete surgical excision is warranted. Hemangiopericytomas display a rich vascular pattern and stain positive for factor VIIIa. They are negative for desmin and actin. The clinical behavior of these lesions is difficult to predict, but metastases may develop in 20% to 50% of cases. Those lesions with more than four mitoses per 10 high-power field have a worse prognosis (Enzinger and Smith, 1976; Zirkin 1977).
Diagnosis
Because of their slow growth and anatomic location, retroperitoneal tumors (usually sarcomas) tend to grow to a large size before they are detected. In one series of soft tissue sarcomas the average size at diagnosis for extremity lesions was 5 cm, whereas retroperitoneal lesions were 16.5 cm (Hueman et al, 2008); thus such lesions can often be enormous by usual pathologic standards. Although the age at presentation is distributed across a large spectrum, the majority of patients are diagnosed with retroperitoneal tumors in the sixth decade of life. Because the progression of symptoms is slow there is usually a lag time of 5 months from initial symptoms to diagnosis. The principal clinical finding is an abdominal mass and abdominal pain (60% to 80%) (McGrath, 1984). Many patients also experience nausea and vomiting and weight loss (20% to 30%). Neurologic findings are noted in 30% of patients (Cohan et al, 1988